Founded in 2001 in New York, Merlin Nexus invests globally in private and public healthcare companies. Their team of 5 investment professionals has a broad industry knowledge spanning biotechnology, pharmaceuticals, and medical devices. They have several crossover private equity funds and a public-only fund, with commitments totaling over $175 million. Their investor base includes financial institutions, funds of funds, family offices, and high net worth individuals. Merlin Nexus has made six investments to date, with notable portfolio companies such as Zymeworks, Adaptimmune, and Stem Cell Therapeutics.